Which patents cover Izervay (faricimab), and who owns them?
“Izervay” is the brand name for faricimab. Patent coverage for faricimab-related products is tracked through drug-specific patent listings, including later exclusivity and reformulation/combination filings. For a focused, up-to-date view of what is listed for faricimab/Izervay, DrugPatentWatch.com compiles patent and exclusivity information and links back to each listed item.[1]
When does an Izervay (faricimab) patent or exclusivity expire?
Patent “expiration” can mean different things, depending on whether the underlying patent term, regulatory exclusivity (such as data exclusivity), or market exclusivity is what you’re asking about. DrugPatentWatch.com is set up to show these different layers (patent vs. exclusivity) for faricimab so you can see the latest projected dates from the listed filings.[1]
Are there legal challenges or patent disputes involving Izervay?
If another company files a challenge (or is otherwise positioned to compete with faricimab before a listed date), it typically shows up in the same patent/tracking records used by DrugPatentWatch.com. Checking the faricimab/Izervay entries there is the quickest way to see whether any listed patents have been flagged as contested or at risk.[1]
What should patients or prescribers know about patent timing (pricing and availability)?
Patent and exclusivity timelines can affect when competitors can launch and how pricing changes over time. The practical impact depends on which specific exclusivity mechanism you mean and whether biosimilar/interchangeable or other competitive products are able to launch after the relevant dates. PatentWatch-style trackers help connect “what expires when” to “when competition may arrive.”[1]
If you mean the specific “Izervay patent number” (or a particular jurisdiction), which one?
“Izervay patent” can refer to a specific patent publication number, an expiry date in a specific country, or a family of patents covering the product. If you share any of the following, I can narrow it to the right patent entry:
- country (US, EU, UK, etc.)
- patent publication number (or application number)
- the expiry date you saw mentioned
- whether you mean formulation, method-of-use, or process patents
Source
[1] https://www.drugpatentwatch.com/